Hélène Verdoux, Peter Schulte, Alexis Lepetit, François Montastruc, Jose de Leon
10 min
Clozapine is the gold-standard treatment for treatment-resistant schizophrenia, known for reducing all-cause, suicide, and cardiovascular mortality. However, clinicians often face uncertainty when patients on clozapine develop cancer, particularly regarding the safety of continuing the medication during chemotherapy. This systematic review synthesized available evidence to clarify the risks of cancer in clozapine users and provide guidance for clinical management, including the prevention of adverse drug reactions and the navigation of drug-drug interactions.
Recent pharmacovigilance and population-based studies have identified a statistical association between long-term clozapine exposure and an increased risk of hematological malignancies, specifically lymphomas. While some evidence suggests a dose-response relationship, the absolute risk remains very low (e.g., approximately 0.7% over 12 years in one large cohort). The authors emphasize that this small potential risk does not outweigh the well-established survival benefits of clozapine. Furthermore, studies on non-hematological cancers, such as breast or hepatocellular carcinoma, have generally not shown an increased risk linked to clozapine.
A major finding is that clozapine-related neutropenia and chemotherapy-induced neutropenia have distinct clinical profiles. Clinicians are advised that neutropenia occurring during the anticipated nadir of chemotherapy should be attributed to the anti-cancer drugs, not clozapine. Discontinuing clozapine in these scenarios often leads to psychiatric decompensation, which can severely impede a patient's ability to undergo necessary cancer treatment. The review advocates for close multidisciplinary collaboration between psychiatric, oncologic, and pharmacy teams to maintain clozapine therapy whenever possible.
Beyond the specific concern of neutropenia, the paper highlights that other complications—such as clozapine intoxication caused by infection, systemic inflammation, or changes in tobacco use—are potentially more lethal and require vigilance. Systematic therapeutic drug monitoring (TDM) is strongly recommended during cancer care to manage fluctuating serum concentrations, especially in the context of physiological changes like kidney or liver impairment, weight loss, or the introduction of new medications.
OBJECTIVES: The safety profile of clozapine raises specific questions regarding risk and management of cancer. We aimed to synthesize the information on cancer in clozapine users relevant for clinical practice. METHODS: Articles were identified with MEDLINE and Web of Sciences from inception through December 2025 (PROSPERO CRD420251247617). We included articles on cancer addressing issues related to risk, diagnosis and treatment of cancer in clozapine users, and management of drug-drug interactions (DDI) and adverse drug reactions. Data were synthesized narratively. RESULTS: We identified 73 articles of which most were case reports (n = 41). Long-term clozapine use is associated with a small increased risk of hematological malignancies (HM), but the existence of a causal link, if any, is not yet established. The literature on cancer care is mostly focused on the risk of neutropenia. Initiating myelosuppressive anti-cancer drugs should not lead to clozapine discontinuation, since there is no evidence of any additive interaction, and adequate curative or palliative treatment of cancer may be dramatically impeded by psychotic decompensation. Few studies have investigated other potentially lethal risks associated with clozapine use at all stages of cancer, such as constipation or intoxication due to DDI or cancer-related factors (smoking cessation, weight loss, inflammation, etc.). CONCLUSIONS: Considering the reduced mortality associated with clozapine use, the very low absolute risk of HM should not discourage its use. Further studies are needed to determine the most effective strategies for preventing, diagnosing, and treating cancer in clozapine users, in order to provide clinicians with structured guidelines.
Sam: A consistent association deserves attention. But what does the risk look like in absolute terms, against other antipsychotics?
Alex: In a Finnish cohort, blood cancers occurred in about zero point seven percent of clozapine users. The corresponding proportion among users of other antipsychotics was about zero point five percent. Those are observed proportions, not proof that clozapine caused the difference.
Sam: And the time window matters. Those proportions would mean something very different over months than over many years.
Alex: The cohort’s average follow-up was about twelve years. The authors emphasize that the absolute risk was very low. They also place it alongside the reduced all-cause mortality associated with clozapine, rather than treating cancer risk as the whole benefit-risk calculation.
Sam: What stops us from calling that a causal effect, especially if risk also rises with longer exposure?
Alex: Several things. Clinicians may report blood cancers more readily because clozapine already has a reputation for blood-related adverse effects. Regular blood testing could also increase detection. And the observational analyses did not account for all potentially relevant differences, including smoking history and body mass index.
Sam: So replication and an exposure-response pattern strengthen the signal, but they don’t eliminate confounding. The review supports informing patients, not presenting causation as settled.
Alex: The authors make that distinction explicitly. They recommend explaining the possible risk in absolute terms, alongside the mortality benefits. They also suggest using the lowest effective dose and recognizing warning symptoms such as swollen lymph nodes, night sweats, and unexpected weight loss.
Sam: Clozapine users already have blood monitoring. Does that mean these cancers are usually caught through routine tests?
Alex: Not in the cases described here. Most diagnoses followed other symptoms, including weight loss, swollen nodes, or pain. Blood monitoring may help detect leukemia early, but the authors say that is unlikely for lymphoma. So they expect relaxed monitoring rules to have a limited effect on detection, while acknowledging the need for investigation.
Sam: Now to the treatment decision. If both chemotherapy and clozapine can lower neutrophils, why argue against automatically stopping clozapine?
Alex: Because the same abnormal blood count can arise through different processes. Chemotherapy suppresses blood-cell production as part of its effects on dividing cells. Clozapine-related severe neutropenia has a different pattern, with risk concentrated early in treatment. The authors find no evidence of an additive or synergistic interaction increasing clozapine-related neutropenia.
Sam: No evidence of an interaction is not evidence that the combination is harmless. What makes that distinction usable in an actual patient?
Alex: Timing is one practical clue. Consider someone established on clozapine who develops severe neutropenia at chemotherapy’s anticipated nadir, the lowest blood-cell count after treatment. The review says chemotherapy should initially be considered the cause. Persistence beyond the expected recovery period would change that assessment.
Sam: That avoids blaming the longstanding medicine simply because its label mentions the same adverse effect. But what evidence shows that stopping it creates problems?
Alex: In an earlier review summarized here, mental health deteriorated after discontinuation in twelve of thirteen cases. Other antipsychotics often failed to control returning symptoms. In several reports, psychiatric deterioration impeded cancer treatment, sometimes with lasting consequences for adherence.
Sam: Those reports make the potential harm concrete, but they cannot establish the safest strategy for every patient. Were there serious complications during combined treatment too?
Alex: Yes. The reviewed reports included infectious complications and a fatal case associated with neutropenia. Continuation is not a claim of zero risk. It requires individualized assessment, close monitoring, and collaboration between psychiatry, oncology, and hospital pharmacy.
Sam: And there’s a regulatory complication. Does the review’s clinical recommendation line up with the prescribing restrictions?
Alex: Not necessarily. European product information prohibits combining clozapine with agents known to suppress bone marrow. Continuation during such chemotherapy is therefore off-label, and local rules may require a waiver. The authors emphasize transparent discussion with patients and relatives.
Sam: The review also warns that concentrating on neutropenia can obscure other dangers. Which ones change the picture most?
Alex: Severe constipation and clozapine intoxication deserve attention. Cancer-related inflammation, infection, weight loss, and organ failure can alter how the body handles clozapine. So can stopping smoking, because tobacco smoke increases the activity of an enzyme involved in its metabolism.
Sam: Smoking cessation remains a prevention priority in the review. But a beneficial change can still require medication adjustment.
Alex: One case makes that vivid. After smoking cessation, symptoms of clozapine intoxication were initially mistaken for terminal cancer symptoms. Measuring the drug level revealed the problem. The review recommends therapeutic drug monitoring, meaning blood-level measurements to guide dosing, alongside clinical observation.
Sam: That also connects to diagnosis. If constipation or weight loss already has an apparent explanation, clinicians could overlook a different cause.
Alex: The authors warn about that masking effect. Unexpected onset or worsening of symptoms should prompt investigation, rather than automatic attribution to clozapine. They also describe a patient initially denied a stem-cell transplant because of stigmatizing assumptions about schizophrenia and its treatment. Family and psychiatric-team advocacy helped reverse that decision.
Sam: Given the uneven evidence, who should read the full review, and where should they start?
Alex: Researchers and clinicians working across psychiatry, oncology, and pharmacy should read it. Start with “Management of cancer in clozapine users,” especially the distinction between chemotherapy-related and clozapine-related neutropenia. Then read the discussion of blood-cancer risk and confounding. This is a useful clinical synthesis, not definitive comparative safety evidence.
Sam: And what should everyone else remember when this risk signal comes up?
Alex: A possible rare cancer risk is not a reason for automatic clozapine withdrawal during cancer treatment. Protecting psychiatric stability can be part of protecting access to cancer care.
Sam: Thanks for listening.